Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
901-920 of 1,694 trials

RECLAIM: Treatments for Long COVID

We are studying different treatments for people suffering from long COVID to see how they improve physical and mental health. The trial will also assess specific symptoms like fatigue and cognitive difficulties.

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Atrial Fibrillation After Aortic Valve Surgery: Atorvastatin Study

We are investigating whether taking atorvastatin before surgery helps reduce the risk of atrial fibrillation in patients undergoing aortic valve replacement. We also want to see how stopping statins affects complications after surgery.

Atrial Fibrillation and FlutterPatients Undergoing Surgical Aortic Valve Replacement≤3 monthsMonitoring phase (IV)Standard MedicinesCardiology

Multiple Myeloma: Selinexor with Dexamethasone and Bortezomib

We are studying different combinations of Selinexor, Dexamethasone, and Bortezomib for patients with hard-to-treat multiple myeloma. Our goal is to see how well these treatments work and how safe they are.

Multiple MyelomaRelapsed/Refractory Multiple MyelomaPenta-Refractory Multiple Myeloma3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Locally-Advanced Rectal Cancer: Tailored Treatment Study

We are studying a personalized treatment plan for patients with locally-advanced rectal cancer who respond well to initial chemotherapy. The goal is to see if this approach maintains effective surgery outcomes while reducing treatment intensity.

Rectal Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Esophageal Adenocarcinoma: Metformin Treatment

We are studying whether metformin can enhance the immune response in patients with esophageal adenocarcinoma receiving chemoradiotherapy. This research may help improve treatment effectiveness and patient outcomes.

Oesophageal Adenocarcinoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Daratumumab for Very High-Risk T-Cell Acute Lymphoblastic Leukemia

We are studying whether adding daratumumab to standard treatment helps adults with very high-risk T-ALL achieve better disease control. This trial will also assess the safety and effectiveness of this combination therapy.

Very High-Risk T-Lineage Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Plasmablastic Lymphoma: Daratumumab with Bortezomib and Dexamethasone

We are studying a combination of daratumumab, bortezomib, and dexamethasone for patients with relapsed or refractory plasmablastic lymphoma. The goal is to see if this treatment improves outcomes for those who cannot undergo stem cell transplantation.

Relapsed or Refractory Plasmablastic Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Prostate Cancer: PF-06821497 with Enzalutamide

We are studying a new treatment combining PF-06821497 with enzalutamide for men with advanced prostate cancer previously treated with abiraterone. The goal is to see if this combination can improve survival and reduce tumor activity compared to standard therapies.

Castration-resistant Prostate Cancer6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Prostate Cancer: Radium-223 and Docetaxel Study

We are exploring whether using Radium-223 followed by Docetaxel helps men with bone-only metastatic prostate cancer feel better and live longer. This study will compare the effects of these treatments on quality of life and survival.

Metastatic Castration-Resistant Prostate CancerSymptomatic Bone-Only Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Cirrhosis: Carvedilol for Prevention

We are studying whether low-dose carvedilol can help prevent complications or death in patients with asymptomatic cirrhosis. This trial focuses on individuals with specific liver conditions to see if the medication is effective and safe.

Alcoholic Cirrhosis>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementHepatologyInternal Medicine

Anorexia Nervosa: Donepezil Treatment Study

We are investigating whether donepezil can help improve symptoms and support weight gain in adult women with anorexia nervosa. This study compares its effects to a placebo to understand its potential benefits.

Anorexia Nervosa3-6 monthsEfficacy phase (II)Standard MedicinesPsychiatry

Multiple Sclerosis in Kids: Ofatumumab and Siponimod Study

We are comparing two new treatments, ofatumumab and siponimod, to fingolimod in children with multiple sclerosis. The study aims to see if these new options are as effective and safe for managing their condition.

Multiple Sclerosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Myelofibrosis: Testing RVU120

We are studying the investigational drug RVU120 for patients with myelofibrosis to see if it helps reduce cancer symptoms and improve treatment outcomes. This trial will also assess its safety and effectiveness when used alone or with another medication.

MyelofibrosisEfficacy phase (II)No PlaceboInvestigational MedicinesHematology

Dexamethasone for Congenital Adrenal Hyperplasia in Pregnancy

We are studying whether a lower dose of dexamethasone can effectively prevent prenatal complications in female babies with congenital adrenal hyperplasia. We will also monitor the health of mothers and their children during and after pregnancy.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyGynecology and Obstetrics

High Blood Pressure: Irbesartan and Amlodipine Combination

We are testing a new fixed-dose pill combining irbesartan and amlodipine for patients with high blood pressure. The goal is to see if it effectively lowers blood pressure and is safe for use.

High Blood Pressure1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Enterococcus faecalis Endocarditis: Continuous Infusion Antibiotics Study

We are studying whether continuous infusion of ampicillin and ceftriaxone is as effective as standard treatment for patients with Enterococcus faecalis infective endocarditis. This may help improve treatment outcomes and reduce complications.

Enterococcal Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Lung Fibrosis: ENV-101 Treatment Study

We are testing a new medication, ENV-101, for people with lung fibrosis to see if it improves lung function and overall health. The study will also look at the safety of this treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Kidney Disease: Frexalimab, Brivekimig, and Rilzabrutinib Study

We are testing three new medications for people aged 16 to 75 with primary focal segmental glomerulosclerosis or minimal change disease. The goal is to see if they can reduce protein in urine and improve kidney function compared to a placebo.

Focal Segmental Glomerulosclerosis (FSGS)Minimal Change Disease (MCD)Immune System Diseases1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Ovarian Cancer: Olaparib and Durvalumab Study

We are exploring whether Olaparib alone or with Durvalumab can be safely given to patients with high-grade ovarian cancer before surgery. This study may help us learn more about treatment effectiveness and safety.

Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Heart Attack Treatment: Timing of Medications

We are studying how the timing of beta blockers, ACE inhibitors, and SGLT2 inhibitors affects heart function in people who have had a heart attack. This may help us understand the best way to use these medications for better recovery.

Heart Attack>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine